Clinical trials: recruiting
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Pancreatic Cancer, Pancreatic Cancer Metastatic
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- MAPKeeper 301 (NCT07562152)
- Testing
- Atebimetinib, GnP, mGnP
- Where
- 72 sites in United States, Australia and 7 more
- Volunteers
- 570 people
- Sponsor
- Immuneering Corporation
Major Depressive Disorder
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Trial name
- NCT06966401
- Testing
- NBI-1065845
- Where
- 120 sites in United States, Australia and 21 more
- Volunteers
- 850 people
- Sponsor
- Neurocrine Biosciences
Locally Advanced or Metastatic Solid Tumors
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in…
- Trial name
- NCT06349811
- Testing
- BL-M05D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Atopic Dermatitis
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and…
- Trial name
- ARMADA-AD (NCT07290803)
- Where
- 82 sites in United States, Canada and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Rett Syndrome
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
- Trial name
- NCT07503444
- Testing
- fenfluramine hydrochloride
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 200 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Where
- 15 sites in United States
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Digital Eye Strain (DES)
Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue
With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern.
- Trial name
- NCT07737938
- Testing
- BL531_low dose, BL531_high dose, LR1349_low dose
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Synbio Tech Inc.
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 38 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 103 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Cancer-associated Cachexia
Visugromab in Cachexia International Trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia.
- Trial name
- VINCIT (NCT07112196)
- Testing
- Visugromab (CTL-002)
- Where
- 79 sites in United States, Bulgaria and 12 more
- Volunteers
- 518 people
- Sponsor
- CatalYm GmbH
Systemic Sclerosis, Idiopathic Inflammatory Myopathies
A Study of AZD0120 in Autoimmune Diseases
This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc)…
- Conditions
- Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Trial name
- AURORA (NCT07295847)
- Testing
- AZD0120, SOC
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Crohn's Disease
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China.
- Trial name
- NCT05837897
- Testing
- Vedolizumab IV
- Where
- 43 sites in China
- Volunteers
- 408 people
- Sponsor
- Takeda
Small Cell Lung Cancer, Neuroendocrine Tumors
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M14D1 in…
- Trial name
- NCT06505824
- Testing
- BL-M14D1
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Small Cell Lung Cancer ( SCLC )
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with paclitaxel to treat people with SCLC.
- Trial name
- ALISCA-Lung2 (NCT07465757)
- Testing
- Alisertib, Paclitaxel
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Puma Biotechnology, Inc.
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
- Trial name
- SUPPORT II (NCT07296744)
- Testing
- The Supira System, Impella
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Supira Medical
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.
- Trial name
- NCT06430801
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 499 sites in United States, Australia and 45 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinsons Disease (PD)
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
- Trial name
- exPDite-2 (NCT06944522)
- Testing
- bemdaneprocel
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 102 people
- Sponsor
- BlueRock Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.